---
schema_version: "secwatch.filing_event.v1"
accession: "0001006837-25-000118"
form_type: "8-K"
ticker: "VATE"
cik: "0001006837"
company_name: "INNOVATE Corp."
filed_at: "2025-10-21T23:59:59+00:00"
generated_at: "2026-05-17T02:56:09.524602+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# MediBeacon receives NMPA approval for Transdermal GFR System in China; sales expected by year-end

## Summary
- NMPA approved Lumitrace (relmapirazin) injection and MediBeacon TGFR Monitor/Sensor for kidney function assessment in China.
- TGFR system will be available for sale in China before end of 2025; commercial partnership with Huadong Medicine (est. 2019).
- CKD affects ~11% of China's 1.4B people; TGFR offers point-of-care tGFR without blood draws or estimating equations.

## SEC filing metadata
- accession: 0001006837-25-000118
- form_type: 8-K
- ticker: VATE
- cik: 0001006837
- company_name: INNOVATE Corp.
- filed_at: 2025-10-21T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1006837/000100683725000118/0001006837-25-000118-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1006837/000100683725000118/hchc-20251021.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001006837-25-000118
- JSON: https://secwatch.observer/filing/0001006837-25-000118.json
- Plain text: https://secwatch.observer/filing/0001006837-25-000118.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.